CH655005A5 - Composizione farmaceutica ad azione metabolica ed energetica utilizzabile in terapia cardiaca e vascolare. - Google Patents

Composizione farmaceutica ad azione metabolica ed energetica utilizzabile in terapia cardiaca e vascolare. Download PDF

Info

Publication number
CH655005A5
CH655005A5 CH858/83A CH85883A CH655005A5 CH 655005 A5 CH655005 A5 CH 655005A5 CH 858/83 A CH858/83 A CH 858/83A CH 85883 A CH85883 A CH 85883A CH 655005 A5 CH655005 A5 CH 655005A5
Authority
CH
Switzerland
Prior art keywords
carnitine
coenzyme
pharmaceutical composition
metabolic
cardiac
Prior art date
Application number
CH858/83A
Other languages
English (en)
Italian (it)
Inventor
Alberto Bertelli
Original Assignee
Sigma Tau Ind Farmaceuti
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sigma Tau Ind Farmaceuti filed Critical Sigma Tau Ind Farmaceuti
Priority to CH858/83A priority Critical patent/CH655005A5/it
Priority to IT23559/83A priority patent/IT1170235B/it
Priority to US06/578,588 priority patent/US4599232A/en
Priority to GB08403668A priority patent/GB2137088B/en
Priority to NL8400488A priority patent/NL192778C/nl
Priority to SE8400851A priority patent/SE457143B/sv
Priority to DE19843405581 priority patent/DE3405581A1/de
Priority to DK072284A priority patent/DK165167C/da
Priority to JP59026179A priority patent/JPS59186914A/ja
Priority to FR8402347A priority patent/FR2543827B1/fr
Priority to BE2/60334A priority patent/BE898918A/nl
Publication of CH655005A5 publication Critical patent/CH655005A5/it

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/205—Amine addition salts of organic acids; Inner quaternary ammonium salts, e.g. betaine, carnitine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Epidemiology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
CH858/83A 1983-02-16 1983-02-16 Composizione farmaceutica ad azione metabolica ed energetica utilizzabile in terapia cardiaca e vascolare. CH655005A5 (it)

Priority Applications (11)

Application Number Priority Date Filing Date Title
CH858/83A CH655005A5 (it) 1983-02-16 1983-02-16 Composizione farmaceutica ad azione metabolica ed energetica utilizzabile in terapia cardiaca e vascolare.
IT23559/83A IT1170235B (it) 1983-02-16 1983-10-31 Composizione farmaceutica ad azione metabolica ed energetica utilizzabile in terapia cardiaca e vascolare
US06/578,588 US4599232A (en) 1983-02-16 1984-02-09 Pharmaceutical composition with metabolic and energetic activity for the use in cardiac and vascular therapy
GB08403668A GB2137088B (en) 1983-02-16 1984-02-13 Pharmaceutical compositions containing a carnitine compound and a ubiquinone coenzyme
NL8400488A NL192778C (nl) 1983-02-16 1984-02-15 Farmaceutisch preparaat dat anti-anoxie-werking heeft en arteriosclerotische beschadigingen remt.
SE8400851A SE457143B (sv) 1983-02-16 1984-02-16 Farmaceutisk komposition med metabolisk, antianoxisk och vaevnadsenergetisk aktivitet innehaallande coenzym q ?711?710 och karnitin eller acetylkarnitin
DE19843405581 DE3405581A1 (de) 1983-02-16 1984-02-16 Pharmazeutische zusammensetzung mit metabolischer und energetischer wirksamkeit zur verwendung in der herz- und gefaesstherapie
DK072284A DK165167C (da) 1983-02-16 1984-02-16 Farmaceutisk middel med metabolisk og energetisk virkning indeholdende coenzym q10 og carnitin eller acetylcarnitin
JP59026179A JPS59186914A (ja) 1983-02-16 1984-02-16 心臓及び血管系の治療に使用するための代謝及びエネルギ−活性を有する医薬組成物
FR8402347A FR2543827B1 (fr) 1983-02-16 1984-02-16 Composition pharmaceutique ayant une activite metabolique et energetique pour utilisation dans la therapeutique cardiaque et vasculaire
BE2/60334A BE898918A (nl) 1983-02-16 1984-02-16 Farmaceutisch preparaat met metabole en energetische activiteit voor toepassing in een hart- en vaattherapie

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CH858/83A CH655005A5 (it) 1983-02-16 1983-02-16 Composizione farmaceutica ad azione metabolica ed energetica utilizzabile in terapia cardiaca e vascolare.

Publications (1)

Publication Number Publication Date
CH655005A5 true CH655005A5 (it) 1986-03-27

Family

ID=4196830

Family Applications (1)

Application Number Title Priority Date Filing Date
CH858/83A CH655005A5 (it) 1983-02-16 1983-02-16 Composizione farmaceutica ad azione metabolica ed energetica utilizzabile in terapia cardiaca e vascolare.

Country Status (11)

Country Link
US (1) US4599232A (enExample)
JP (1) JPS59186914A (enExample)
BE (1) BE898918A (enExample)
CH (1) CH655005A5 (enExample)
DE (1) DE3405581A1 (enExample)
DK (1) DK165167C (enExample)
FR (1) FR2543827B1 (enExample)
GB (1) GB2137088B (enExample)
IT (1) IT1170235B (enExample)
NL (1) NL192778C (enExample)
SE (1) SE457143B (enExample)

Families Citing this family (64)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1209519B (it) * 1984-04-10 1989-08-30 Poli Ind Chimica Spa Composti ad attivita'cardiotrofica.
CH662505A5 (it) * 1985-04-30 1987-10-15 Seuref Ag Composizioni farmaceutiche ad azione protettiva vascolare.
CH670763A5 (enExample) * 1985-08-02 1989-07-14 Seuref Ag
CH666183A5 (it) * 1985-08-06 1988-07-15 Seuref Ag Composizione farmaceutica ad azione protettiva cardiaca e metabolica sul metabolismo energetico muscolare.
IT1184655B (it) * 1985-10-14 1987-10-28 Sigma Tau Ind Farmaceuti Imiego di acetil l-carnitina nel trattamento terapeutico degli stati di shock
SE8703321D0 (sv) * 1987-08-27 1987-08-27 Sockerbolaget Ab Kostforsterkning
JPH02188523A (ja) * 1989-01-13 1990-07-24 M S C:Kk 睡眠時無呼吸症治療薬
GB8907276D0 (en) * 1989-03-31 1989-05-17 Therapy Advisory Services Limi Health supplement
AT393954B (de) * 1990-02-28 1992-01-10 Bock Orthopaed Ind Verfahren und vorrichtung zur bestimmung von gebrauchseigenschaften eines prothesenschaftes
IT1254314B (it) * 1992-03-27 1995-09-14 Sigma Tau Ind Farmaceuti Composizioni farmaceutiche conyenenti l-carnitina e acil- carnitine inassociazione con ace-inibitori per il trattamento di patologie cardiovascolari.
EP0643775B1 (en) * 1992-05-28 2004-07-21 Centre For Molecular Biology And Medicine, Quinone derivatives for enhancing cellular bioenergy
DE4335454A1 (de) * 1993-10-19 1995-04-20 Schleicher Peter Geriatrikum
US5707971A (en) * 1995-06-07 1998-01-13 Life Resuscitation Technologies, Inc. Modulation of glycolytic ATP production
US6080788A (en) * 1997-03-27 2000-06-27 Sole; Michael J. Composition for improvement of cellular nutrition and mitochondrial energetics
NZ338026A (en) * 1997-03-27 2001-09-28 Michael J Sole Nutritional composition comprising L-carnitine, ubiquione and taurine and use for treating organ systems
IT1291127B1 (it) * 1997-04-01 1998-12-29 Sigma Tau Ind Farmaceuti Integratore alimentare per soggetti dediti ad intensa e prolungata attivita' fisica
US5889055A (en) * 1997-04-04 1999-03-30 Howard; James R. L-carnitine and acetyl-L-carnitine combined for prevention and treatment of syndromes related to diseases of energy metabolism
US5973004A (en) * 1997-04-04 1999-10-26 Howard; James R. L-carnitine, acetyl-L-carnitine, and pantothenic acid or ubiquinone, combined for prevention and treatment of syndromes related to ineffective energy metabolism
US5916912A (en) * 1997-06-16 1999-06-29 The Regents Of The University Of California Dietary composition for enhancing metabolism and alleviating oxidative stress
US7371415B1 (en) 1998-04-03 2008-05-13 The Daily Wellness Company Method and composition for improving sexual fitness
US20050196470A9 (en) * 1998-04-03 2005-09-08 Wuh Hank C Method and composition for enhancing sexual desire
WO1999051252A1 (en) 1998-04-03 1999-10-14 The Daily Wellness Company Compositions comprising l-arginine, ginseng and gingko biloba for enhancing blood circulation
IT1299266B1 (it) 1998-05-15 2000-02-29 Sigma Tau Ind Farmaceuti Inibitori reversibili della carnitina palmitoil trasferasi
US6616942B1 (en) 1999-03-29 2003-09-09 Soft Gel Technologies, Inc. Coenzyme Q10 formulation and process methodology for soft gel capsules manufacturing
US20070072927A1 (en) * 1999-09-23 2007-03-29 Vita Joseph A Nutritional supplement for increased energy and stamina
AU7828200A (en) 1999-09-23 2001-04-24 Juvenon Corporation Nutritional supplement for increased energy and stamina
US6562869B1 (en) 1999-09-23 2003-05-13 Juvenon, Inc. Nutritional supplement for increased energy and stamina
WO2001032168A1 (en) 1999-11-03 2001-05-10 Juvenon, Inc. Method of treating benign forgetfulness
US6740338B1 (en) 2000-01-20 2004-05-25 Raj K. Chopra Reduced form of Cenzyme Q in high bioavailability stable oral dosage form
US8753675B1 (en) * 2000-01-20 2014-06-17 Raj K. Chopra Reduced form of Coenzyme Q in high bioavailability stable dosage forms and related applications
US20010043983A1 (en) * 2000-01-25 2001-11-22 Hamilton Nathan D. Nutritional supplements for aged pets
DE10036798A1 (de) * 2000-07-28 2002-02-07 Beiersdorf Ag Mittel zur Behandlung der Haare und der Kopfhaut
US6441050B1 (en) 2000-08-29 2002-08-27 Raj K. Chopra Palatable oral coenzyme Q liquid
US6989164B2 (en) 2000-12-22 2006-01-24 The Daily Wellness Company Method and composition for improving male fertility health
US6497885B2 (en) 2000-12-22 2002-12-24 The Daily Wellness Company Method and composition for improving fertility health in female and male animals and humans
US6579866B2 (en) 2000-12-28 2003-06-17 Mccleary Larry Composition and method for modulating nutrient partitioning
US20040043013A1 (en) 2000-12-28 2004-03-04 Mccleary Edward Larry Metabolic uncoupling therapy
US20060062864A1 (en) * 2000-12-28 2006-03-23 Mccleary Edward L Weight loss composition and method
DE60237597D1 (de) * 2001-05-10 2010-10-21 Kaneka Corp Zusammensetzungen für die transmukosale verabreichung mit coenzym q als wirkstoff
EP1407782A4 (en) * 2001-06-28 2004-10-20 Takeda Chemical Industries Ltd AGENTS FOR PREVENTION / TREATMENT OF FUNCTIONAL ORGANIC DISEASES AND ORGANIC DYSFUNCTION
US8703209B2 (en) * 2003-06-17 2014-04-22 Edward Larry McCleary Composition and method for modulating hydrogen ion physiology
WO2005006890A2 (en) * 2003-07-10 2005-01-27 Forest Carl A Foods, beverages, condiments, spices and salad dressings with specialized supplements
US20080089877A1 (en) * 2003-08-14 2008-04-17 Udell Ronald G Super Absorption Coenzyme Q10
US8105583B2 (en) * 2003-09-29 2012-01-31 Soft Gel Technologies, Inc. Solubilized CoQ-10
US7169385B2 (en) * 2003-09-29 2007-01-30 Ronald G. Udell Solubilized CoQ-10 and carnitine
US8124072B2 (en) 2003-09-29 2012-02-28 Soft Gel Technologies, Inc. Solubilized CoQ-10
US20050232911A1 (en) * 2004-04-19 2005-10-20 Schreiber Brian D Prevention and treatment of metabolic abnormalities associated with excess intramyocellular lipid
WO2006012267A1 (en) * 2004-06-29 2006-02-02 Elixirin Corporation Dietary compositions for enhancing metabolism and reducing reactive oxygen species
WO2006130775A2 (en) 2005-06-01 2006-12-07 Edison Pharmaceuticals, Inc. Redox-active therapeutics for treatment of mitochondrial diseases and other conditions and modulation of energy biomakers
US20050249803A1 (en) * 2005-06-03 2005-11-10 Udell Ronald G Soft gel capsules containing polymethoxylated flavones and palm oil tocotrienols
US7887852B2 (en) * 2005-06-03 2011-02-15 Soft Gel Technologies, Inc. Soft gel capsules containing polymethoxylated flavones and palm oil tocotrienols
US7432305B2 (en) * 2005-09-15 2008-10-07 Edison Pharmaceuticals, Inc. Tail variants of redox-active therapeutics for treatment of mitochondrial diseases and other conditions and modulation of energy biomarkers
TW200735863A (en) * 2006-01-13 2007-10-01 Elixirin Corp Dietary compositions for enhancing metabolism and reducing reactive oxygen species
EA019675B1 (ru) 2006-02-22 2014-05-30 Эдисон Фармасьютикалз, Инк. Редокс-активные терапевтические средства для лечения митохондриальных заболеваний и модуляции биомаркера коэнзима q
US20080020022A1 (en) * 2006-06-05 2008-01-24 Udell Ronald G Chewable co-enzyme q-10 capsule
US7615324B2 (en) * 2007-03-14 2009-11-10 Fujifilm Corporation Photosensitive composition, and cured relief pattern production method and semiconductor device using the same
US8343541B2 (en) 2007-03-15 2013-01-01 Soft Gel Technologies, Inc. Ubiquinol and alpha lipoic acid compositions
ES2306610B1 (es) * 2007-04-16 2009-09-11 Universidad De Sevilla Uso de la l-carnitina para el tratamiento de la hipertension arterial.
TW200918096A (en) * 2007-06-22 2009-05-01 Kaneka Corp Composition comprising bioactive substance
EP2172196B1 (en) * 2007-06-22 2020-03-25 Kaneka Corporation Composition containing coenzyme q10
EP2186789B1 (en) * 2007-08-22 2013-12-25 Kaneka Corporation Method of producing reduced coenzyme q10 and method of stabilizing the same
WO2009104696A1 (ja) * 2008-02-19 2009-08-27 株式会社アーネストメディスン 身体機能の回復に有用な経口又は経腸組成物
JP2012502064A (ja) 2008-09-10 2012-01-26 エジソン ファーマシューティカルズ， インコーポレイテッド 酸化還元活性治療剤を用いての広汎性発達障害の処置
CA3008849A1 (en) 2015-12-17 2017-06-22 Bioelectron Technology Corporation Flouroalkyl, flouroalkoxy, phenoxy, heteroaryloxy, alkoxy, and amine 1,4-benzoquinone derivatives for treatment of oxidative stress disorders

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2903558C2 (de) * 1978-02-03 1994-09-01 Sigma Tau Ind Farmaceuti Verwendung von L-Carnitin
IT1206954B (it) * 1979-02-12 1989-05-17 Sigma Tau Ind Farmaceuti Agenti terapeutici a base di un acil derivato della carnitina per la cura di vasculopatie periferiche
US4346107A (en) * 1979-02-12 1982-08-24 Claudio Cavazza Pharmaceutical composition comprising acyl-carnitine for the treatment of impaired cerebral metabolism
IT1142934B (it) * 1981-11-06 1986-10-15 Sigma Tau Ind Farmaceuti Uso della carnitina e delle acilcarnitine inferiori nel trattamento terapeutico della patologia delle vene

Also Published As

Publication number Publication date
JPH027572B2 (enExample) 1990-02-19
NL192778B (nl) 1997-10-01
FR2543827A1 (fr) 1984-10-12
SE8400851L (sv) 1984-08-17
DK72284D0 (da) 1984-02-16
DE3405581A1 (de) 1984-10-18
DE3405581C2 (enExample) 1992-10-22
GB2137088B (en) 1986-02-05
DK165167B (da) 1992-10-19
NL192778C (nl) 1998-02-03
GB8403668D0 (en) 1984-03-14
DK72284A (da) 1984-08-17
IT1170235B (it) 1987-06-03
BE898918A (nl) 1984-08-16
IT8323559A0 (it) 1983-10-31
FR2543827B1 (fr) 1987-06-12
DK165167C (da) 1993-03-01
NL8400488A (nl) 1984-09-17
JPS59186914A (ja) 1984-10-23
SE457143B (sv) 1988-12-05
US4599232A (en) 1986-07-08
GB2137088A (en) 1984-10-03
SE8400851D0 (sv) 1984-02-16

Similar Documents

Publication Publication Date Title
CH655005A5 (it) Composizione farmaceutica ad azione metabolica ed energetica utilizzabile in terapia cardiaca e vascolare.
US4255449A (en) Method of treating abnormal lipoprote in ratios
ES2244103T3 (es) Remedio para enfermedades neurodegenerativas.
US4268524A (en) Method of treating abnormal lipoprotein ratios with acylcarnitine
US5025035A (en) Method of treating depression
GB1596491A (en) Pharmaceutical compositions containing carnitine derivatives
Rossoni et al. The nitroderivative of aspirin, NCX 4016, reduces infarct size caused by myocardial ischemia-reperfusion in the anesthetized rat
ITRM950824A1 (it) Composizione farmaceutica contenente l-carnitina o alcanoil l-carnitine per la prevenzione ed il trattamento di stati morbosi
ES2238268T3 (es) Medicamento para el tratamiento de la hipertension sanguinea.
US3851056A (en) Method of depressing fatty acids and triglycerides
ITRM990230A1 (it) Composizione comprendente una carnitina e glutatione, atta ad aumentare l'assorbimento del glutatione sinergizzandone gli effetti.
EP0845986B1 (en) Pharmaceutical composition containing 3-(2,2,2-trimethylhydrazinium) propionate and gamma-butyrobetaine for the treatment of cardiovascular diseases
HU227042B1 (en) Compostion for the prevention and/or treatment of circulatory disorders, comprising derivatives of l-carnitine and extracts of ginkgo biloba
JPH04506667A (ja) 甲状腺ホルモン心臓治療
IE51711B1 (en) Carnitine derivatives
CH657526A5 (it) Composizione farmaceutica comprendente una alcanoil l-carnitina, per il trattamento terapeutico delle miopatie e distrofie muscolari.
US4474812A (en) Pharmaceutical composition for improving the biochemical and behavioral parameters of senility
ITRM990483A1 (it) Composizione per la prevenzione e cura delle disfunzioni e patologie renali di tipo tossico e funzionale.
CH642847A5 (en) Pharmaceutical composition for the treatment of heart disease
WO2001072288A2 (en) Use of cdp-choline for the treatment of alcohol withdrawal syndrome
CH666184A5 (it) Composizione farmaceutica orale a base di ubichinoni.
WO1988004553A1 (en) Treatment of cardiovascular and cerebral toxicity using calcium modulators
Myburgh, DP & Goldman The anti-arrhythmic efficacy of perhexiline maleate disopyramide and mexiletine in ventricular ectopic activity
HUP0202079A2 (en) Cardioactive composition comprising l-carnitine and its derivatives and crataegus extracts
ES2267796T3 (es) Uso de fibratos para la preparacion de un medicamento util en el tratamiento de insuficiencia cardiaca congestiva.

Legal Events

Date Code Title Description
PL Patent ceased